Trial Profile
A case series of patients of skin infection treated with Dalbavancin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 May 2018
Price :
$35
*
At a glance
- Drugs Dalbavancin (Primary)
- Indications Cellulitis; Skin infections
- Focus Adverse reactions; Therapeutic Use
- 03 May 2018 New trial record
- 24 Apr 2018 Results presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases